UPLC-MS/MS method for simultaneously determining nucleosides and methyl-nucleosides in liver mRNA of Epimedin C-induced liver injury mouse model

Zhizhen Song1,2, Zeyun Li1,2, Xueqian Wen1,2, Ruijuan Liu1,2 and Xin Tian1,2*

Abstract

Background: Epimedin C, one of the main active ingredients of Epimedium, has been reported to have potential hepatotoxicity. However, the mechanism of Epimedin C-induced liver injury has not been studied. mRNA methylation, mainly including N6-methyladenosine and N5-methylcytidine, is implicated in the regulation of many biological processes and diseases. The study of quantifying mRNA methylation alterations in Epimedin C-induced liver injury mice may contribute to clarify the mechanism of its hepatotoxicity. Therefore, an analysis method needs to be established to determine nucleoside and methyl-nucleoside levels in liver mRNA.

Methods: An ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to simultaneously determine six nucleosides (adenosine, uridine, cytidine, guanosine, N6-methyladenosine and N5-methylcytidine) in liver mRNA. Besides, the Epimedin C-induced liver injury mouse model was studied by intragastrical administration Epimedin C at a daily dose of 10 or 40 mg/kg for 4 weeks. The nucleoside samples of the mice liver mRNA were prepared and separated on an UPLC column using 0.1% formic acid water and methanol after enzymatic digestion. Then the sample was detected by a Qtrap 6500 mass spectrometer.

Results: In this method, calibration curves of the six nucleosides showed good linearity over their concentration ranges. The linear ranges were 40–20,000 pg/mL for adenosine, cytidine, N6-methyladenosine and N5-methylcytidine, 0.2–100 ng/mL for guanosine, and 2–1000 ng/mL for uridine. Epimedin C-induced liver injury mouse model was successfully established, which could be proved by the elevation of serum aminotransferase levels, and the increased inflammatory cell infiltration as well as vacuolar degeneration in liver. The N6-methyladenosine and N5-methylcytidine levels, and the ratios of N6-methyladenosine to adenosine and N5-methylcytidine to cytidine of the mice liver mRNA were all significantly increased after Epimedin C treatment.

Conclusion: The established method was successfully applied to the determination of six nucleosides levels in liver mRNA of the Epimedin C-induced liver injury mice model and the control group. The results indicated that mRNA methylation might be associated with Epimedin C-induced liver injury. This study will facilitate the mechanism research on the hepatotoxicity of Epimedin C.

Keywords: UPLC-MS/MS, Epimedin C, Liver injury, Nucleosides, mRNA methylation

*Correspondence: tianx@zzu.edu.cn
1 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Full list of author information is available at the end of the article
Background

In recent years, the incidence of drug-induced liver injury has been dramatically increased due to the surging demand for herbal medicine and health care products [1]. Epimedium, an ancient herb medicine, was wildly used in Asia countries. In China, many herbal prescriptions containing Epimedium have been used for rheumatism, arthritis, osteoporosis, and other diseases [2, 3]. In the past few years, varying degrees of liver damage have been frequently reported in Epimedium consuming patients [4, 5]. However, few studies have been conducted on potential mechanism and underlying substance for its hepatotoxicity. As one of the main active ingredients and quality indicator of Epimedium, Epimedin C has shown strong cytotoxicity to HL-7702 and HepG2 cells [6–8]. Therefore, Epimedin C has been proposed as the substance responsible of Epimedium related liver injury. As far as we known, no Epimedin C-induced liver injury has been reported in animal models, which shall prompt investigation of underlying mechanisms.

Methylation modifications of messenger RNAs (mRNA), another layer of epigenetic regulation in addition to DNA and histone modifications, include N6-methyladenosine (m6A), N5-methylcytidine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), pseudouridine (ψ), and so on [9, 10]. Among the methylation modifications of mRNA, m6A and m5C are the most common internal modifications in eukaryotic mRNA, and have been implicated in a variety of biological processes and diseases [9–11]. For example, m6A alteration was associated with the progression and metastasis of hepatocellular carcinoma [12, 13], and acetaminophen-induced liver injury in mice [14]. Besides, m5C played an important role in regulation of cell stress response, apoptosis, and hepatocellular carcinoma [15, 16]. However, the relationship between mRNA methylation and Epimedin C-induced liver injury is still unknown. It was expected that revealing of m6A and m5C alterations in Epimedin C-induced liver injury may contribute to clarify the liver toxicity mechanism of Epimedin C. In consequence, the content of m6A and m5C in liver mRNA of Epimedin C-induced liver injury mice needs to be quantified.

To the best of our knowledge, some liquid chromatography–tandem mass spectrometry (LC-MS/MS) methods have been reported for the determination of m6A or m5C in total RNA or mRNA [14, 17–22]. However, there are some limitations in those methods. For example, the run time of one sample was long [20], or it need a large amount of mRNA [21, 22], or the lower limit of quantification was high [14]. Therefore, a rapid and sensitive ultra-high performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for determination of six nucleosides in mRNA is necessary to be developed for our study.

In this study, the Epimedin C-induced liver injury mouse model was established, and a selective, rapid and sensitive UPLC-MS/MS method was developed for simultaneous determination of six nucleosides in liver mRNA of the mouse model. This work may provide a new idea for further research on the mechanism of Epimedin C or herbal medicine-induced liver injury.

Materials and methods

Chemicals and reagents

Epimedin C (purity ≥ 98%), used as the dosage administration, was purchased from Cdmust Biology Technology Ltd. (Chengdu, China). Lamivudine (internal standard, IS, Batch No. J0820AS, purity > 99%) was purchased from Meilun Biotechnology company Ltd. (Dalian, China). Adenosine (Batch No. NFVEH-MG, purity > 99%), guanosine (Batch No. DLJPH-CK, purity > 98%), and cytidine (Batch No. 5PV0G-QR, purity > 98%) were purchased from Tokyo Chemical Industry (Shanghai) (Shanghai, China). Uridine (Batch No. LM90Q27, purity 99%), m6A (Batch No. LK70U69, purity 97%), and m5C (Batch No. L370O143, purity 98%) were purchased from J&K Chemical (Shanghai, China). Nuclease P1 and alkaline phosphatase were purchased from Takara Biotechnology (Dalian, China). Methanol (HPLC grade) and Formic acid (chromatographic grade) were obtained from Fisher Scientific (Shanghai, China). Ultra-purified water was used throughout this study and was prepared using a Milli-Q purification system (Millipore, Milford, MA, USA). All of the other chemicals and reagents were of analytical grade.

Animals

Male Balb/c mice (6–8 weeks old and weighing 18.0–22.0 g) were obtained from Beijing HFK bioscience Co., Ltd. (Beijing, China). Mice were kept in cages under controlled conditions of 22 ± 0.5 °C, 50 ± 2.0% RH and maintained with free access to standard laboratory food and water for 1 week before experiments.

Establishment of the Epimedin C-induced liver injury model and experimental groups

Animals were randomly divided into three groups (n = 7 each): the normal control group, the Epimedin C (10 mg/kg) group, and the Epimedin C (40 mg/kg) group. Epimedin C were completely dissolved in 0.9% saline before passing through a 0.22 μm cell strainer. The Epimedin C was intragastrically administered at a single dose of 10 or 40 mg/kg body weight per day. Meanwhile, the normal control mice were given the same volume of saline. After 4 weeks of intragastric administration, all mice...
were sacrificed, then blood samples and liver tissues were collected. The procedures for the present study were approved by the Guide for the Care set by the National Institutes of Health.

Assessment of liver injury
Serum alanine transaminase (ALT) and aspartate transaminase (AST) levels in serum were analyzed using colorimetric tests (Nanjing Jiancheng Bioengineering Research Institute, Nanjing, China). Liver tissues fixed in 4% paraformaldehyde were embedded in paraffin using a tissue procedure, and 4-μm-thick slices were prepared and stained with hematoxylin and eosin (H&E) reagent. Photomicrographs were observed with a light microscope to evaluate liver injury.

UPLC-MS/MS instruments and conditions
The LC was performed using an ExionLC™ analytical (UPLC) system (AB Sciex, USA). Chromatographic separation was carried out on a Kinetex® 2.6 μm Polar C18 100A LC column (100 mm × 2.1 mm i.d.). The flow rate was 0.3 mL/min. The mobile phase included ultra-purified water containing 0.1% formic acid (solvent A) and methanol (solvent B) in a linear gradient. The gradient program was as follows: 0 to 0.5 min, 95% A; 0.5 to 3 min, 95 to 30% A; 3 to 4 min, 30% A; 4 to 4.1 min, 30 to 95% A; 4.1 to 6 min, 95% A. The injection volume was 10 μL and the total run time was 8 min. The temperature of the autosampler was set at 4 °C, and the column temperature was maintained at 40 °C. MS/MS analysis was carried out on a Qtrap 6500 mass spectrometer (AB Sciex, Redwood City, CA, USA) equipped with Turbo Ionspray interface operating in positive ESI mode. The instrument was operated with an ion spray voltage of 4.5 kV and a heater gas temperature of 500 °C. Mass-dependent parameters (declustering potential, entrance potential, collision energy, and collision cell exit potential) were set to the optimal values obtained by automated optimization. Data acquisition was achieved by multiple reaction monitoring (MRM). The precursor-product ion pair and the optimal values of mass parameters are listed in Table 1. Positive ion mode was used and the dwell time was set at 100 ms. Data acquisition was generated and processed using the Analyst 1.6.2 software (AB Sciex).

Preparation of calibration standards and QC samples
Stock solutions for calibration and quality control (QC) were accurately weighed and dissolved in dimethylsulfoxide (2% of the total volume) before adding an appropriate volume of methanol to final concentration of 1 mg/mL. Working solutions were prepared by serially diluting the stock solutions with water, and then the corresponding working solutions were mixed to prepare mixed working solutions with concentration in the ranges of 160–80,000 pg/mL for A, C, m5C and m6A, 0.8–400 ng/mL for G, and 8–4000 ng/mL for U. The stock solution (1 mg/mL) of the IS was dissolved in water to 4 ng/mL containing 0.4% formic acid. All solutions were kept at −20 °C and brought to room temperature before use. The calibration standards were prepared by spiking 7.5 μL of the corresponding working solutions mentioned above into 22.5 μL of mixtures of nuclease P1 (0.1 U) and alkaline phosphatase (2 U) to yield concentrations of 40, 120, 500, 1000, 2000, 4000, 8000 and 20,000 pg/mL for A, C, m5C and m6A, 0.2, 0.6, 2.5, 5, 10, 20, 40 and 100 ng/mL for G, and 2, 6, 25, 50, 100, 200, 400 and 1000 ng/mL for U. The QC samples were prepared in the same way as the calibration samples at three concentrations 120, 1600, 16,000 pg/mL for A, C, m5C and m6A, 0.6, 8, 80 ng/mL for G, 6, 80, 800 ng/mL for U.

RNA isolation from liver tissues and Enzymatic digestion of the mRNA
100 mg of liver tissue was completely disrupted and homogenized into 1 mL TRIZol reagent. Then, the total RNA of liver tissue was isolated according to the manufacturer’s instructions. After analyzed by a NanoDrop One (Thermo Scientific), the Dynabeads® mRNA Purification Kit (Ambion) was used to enrich mRNA. The contaminant DNA was removed from the mRNA samples by

| Table 1 | Multiple reaction monitoring transitions and optimized mass parameters for the analytes |
|---------|---------------------------------|
|        | Precursor ion (m/z) | Product ion (m/z) | DP (V) | EP (V) | CE (V) | CXP (V) |
| Adenosine (A) | 268.1 | 136.1 | 30 | 10 | 22 | 10 |
| Uridine (U) | 245.0 | 113.1 | 12 | 10 | 12 | 10 |
| Cytidine (C) | 244.1 | 112.0 | 30 | 10 | 13 | 10 |
| Guanosine (G) | 284.2 | 152.1 | 30 | 10 | 15 | 10 |
| N6-Methyladenosine (m6A) | 282.2 | 150.2 | 30 | 10 | 24 | 10 |
| N5-Methylcytidine (m5C) | 258.2 | 126.1 | 30 | 10 | 15 | 10 |
| Lamivudine (IS) | 230.2 | 112.0 | 30 | 10 | 14 | 10 |

DP declustering potential, EP entrance potential, CE collision energy, CXP collision cell exit potential
using DNase, and the concentration was analyzed by a Qubit 3.0 Fluorometer (Invitrogen).

Referring to the methods reported, enzymatic digestion of the mRNA was performed [14]. The mixture sample was made included 100 ng mRNA, 1 μL of nuclease P1 (0.1 U/μL, Takara), and 2 μL of alkaline phosphatase (calf intestine, 1 U/μL, Takara), and the total volume was brought to 30 μL with ultrapure distilled water. After fully vortexed, the mixtures were incubated at 37 °C for 12 h. Then, 10 μL IS solution (IS, lamivudine, 4 ng/mL) containing 0.4% formic acid was added. The mixtures were vortexed for 15 s and transferred into ultrafiltration tubes (MW cutoff of 3 kDa, Pall Corporation), and centrifuged at 4 °C, 14,000×g for 15 min. The filtrate was added to an autosampler vial, then 10 μL of the filtrate was used for UPLC-MS/MS analysis.

**Method validation**

The analytical methodology was under the guidelines set by the United States Food and Drug Administration [23] and the Chinese Pharmacopoeia Commission [24].

The selectivity was evaluated by comparing chromatograms of mRNA-free blank enzymolysis matrix, blank enzymolysis matrix with all analytes, and a liver mRNA enzymolysis sample containing IS from a mouse after Epimedin C treatment. The absence of peaks at retention times of seven analytes indicated no interference in the test samples.

After detection of the upper limit of the quantification (ULOQ) samples, blank samples were injected to evaluate the carryover effects. The response peak of any analytes must be < 10% of the lower limit of the quantification (LLOQ) samples.

The linearity was investigated by plotting the peak-area ratios of the analytes (A, U, C, G, m5A and m6A) to the IS versus the concentrations of the calibration standards. The calibration equations were fitted using a weighed least-squares linear regression analysis (weighing factor of 1/x^2). The accuracy, expressed as the mean relative error (RE, %), should be ≤ 20% for LLOQ and ≤ 15% for the other seven concentrations of the calibration standards.

To assess the precision and accuracy of the method, five replicates of QC (at three concentration levels) and LLOQ were prepared and analyzed within 3 validation days. Both the accuracy (RE, %) and intra- and inter-precision (RSD, %) for LLOQ should be less than or equal to 20%. The accuracy and precision for the QC levels should be within ±15%.

To determine whether matrix components affected the ion suppression or enhancement in the method, the matrix effect (ME) was assessed by comparing the corresponding peak area responses of enzymolysis matrix with all analytes and the blank samples in which the enzymolysis matrix was replaced with water. In this method, the variability values of the MEs (RSD, %) should be less than 15%.

To evaluate the stability of the analytes in the enzymolysis matrix during sample preparation and storage, the low and high QC concentration levels in different storage conditions were detected. The storage conditions included room temperature for 6 h, three freeze–thaw cycles, autosampler at ambient temperature for 20 h, and freezing at −20 °C for 30 days. The analytes were stable when 85–115% of the initial concentration was retained.

The dilution integrity was assessed by testing the solution which was diluted 100-fold with blank enzymolysis matrix before ultra-filtration from highly concentrated samples above the upper limit of standard curves. The accuracy and precision should be within ±15%.

**Data analysis**

The data were presented as the arithmetic mean ± SD. Statistical analyses were performed using SPSS software for Windows. Statistical significance was assessed by unpaired two-tailed Student’s t-test between two samples. p value < 0.05 was considered statistically significant.

**Results**

**Chromatography and mass spectrometry**

The chromatographic conditions of an UPLC-MS/MS method were important for the chromatographic behavior of the analytes. A Kinetex® 2.6 μm Polar C18 100A LC column was proved to be more suitable for the separation of the targeted compounds in the sample. The composition of mobile phase and the gradient elution programs were optimized to obtain better sensitivity, better peak shape, and mass response to the analytes. Ionization was achieved using the positive ion-monitoring mode with ESI. The precursor ions and product ions of six nucleosides and lamivudine (IS) for the MRM transition were obtained. The MS/MS product ion spectra of the analytes are shown in Fig. 1.

**Method validation**

**Selectivity, linearity, and carryover**

Typical chromatograms of six nucleosides and lamivudine (IS) are shown in Fig. 2. No significant interference was observed at the retention times of A, U, C, G, m5A, m5C and IS which were 1.73, 1.31, 0.91, 1.94, 2.46, 1.07 and 1.56 min, respectively. The calibration curves were linear over the concentration ranges of 40–20,000 pg/mL (r > 0.99, n = 8) for A, C, m5C and m5A, 0.2–100 ng/mL for G, and 2–1000 ng/mL for U (r > 0.99, n = 8). Carryover effects were absent for analytes.
Accuracy and precision

Three batches of LLOQ and QC samples were evaluated to obtain the intra- and interday precision and accuracy with the current method. The validation results of accuracy and precision for A, U, C, G, \( m^6 \)A and \( m^5 \)C are listed in Table 2, which demonstrated that the values of RSD and RE were all inside the acceptable variability limits. It indicates that the method is accurate and precise.
Fig. 2  Typical MRM chromatograms of A, U, C, G, m$^{6}$A, m$^{5}$C and lamivudine (IS). A Blank enzymolysis matrix sample; B blank enzymolysis sample mixed with the six nucleosides and IS; C a liver mRNA enzymolysis matrix sample from Epimedin C-treated mouse.
Matrix effects and stability
The results of ME and extraction recovery were evaluated using QC samples at the low and high QC levels. The IS-corrected matrix factors of the six different batches of enzymolysis matrix at low- and high-concentrations were 96.1 ± 3.1 and 97.8 ± 3.1% for A, 105.4 ± 8.3 and 100.0 ± 3.2% for U, 100.2 ± 7.5 and 97.1 ± 4.2% for C, 100.1 ± 4.6 and 98.6 ± 4.9% for G, 98.3 ± 3.0 and 98.5 ± 3.7% for m6A, and 100.5 ± 5.0 and 95.0 ± 3.9% for m5C, respectively. These data indicated that the MEs for all the analytes were negligible following the current method.

The stability results of the analytes are summarized in Table 3. A, U, C, G, m6A and m5C remained stable at room temperature for 6 h and after three freeze–thaw cycles. All the analytes were also stable in the autosampler at ambient temperature for 20 h and after freezing at −20 °C for 30 days.

Dilution integrity
Results of the dilution integrity were shown in Table 4. The precision and accuracy of the dilution test at the low and high concentration levels were within the acceptable criteria, indicated that A, U, C, G, m6A and m5C were assayed reliably by diluting 100-fold with blank enzymolysis matrix. Samples could be tested by dilution when the analyte concentration exceeded the linear range of the standard curve.

### Table 2

| Analytes | Concentration levels (mean ± SD, pg/mL) | RSD (%) | RE (%) |
|----------|-----------------------------------------|---------|--------|
|          | Added                                   | Measured| Intra-day | Inter-day | Accuracy |
| Adenosine (A) | 40                                      | 40.8±1.9 | 6.5  | 4.3  | 2.0   |
|           | 120                                     | 133.3±3.1| 3.9  | 2.0  | 11.1  |
|           | 1600                                    | 1792.7±33.7| 3.6  | 1.4  | 12.0  |
|           | 16,000                                  | 15,120.0±270.4| 4.0  | 1.0  | −5.5  |
| Uridine (U) | 2000                                    | 1919.3±96.0| 6.5  | 4.7  | −4.0  |
|           | 6000                                    | 6101.3±220.7| 7.4  | 2.5  | 1.7   |
|           | 80,000                                 | 83,680.0±1235.9| 2.6  | 1.2  | 4.6   |
|           | 800,000                                | 710,133.3±10,405.1| 2.1  | 1.3  | −11.2 |
| Cytidine (C) | 40                                      | 36.7±2.3 | 0.5  | 6.8  | −8.3  |
|           | 120                                     | 117.3±5.4 | 4.8  | 4.5  | −2.3  |
|           | 1600                                    | 1672.7±26.0 | 1.5  | 1.6  | 4.5   |
|           | 16,000                                  | 15,953.3±247.5| 1.2  | 1.6  | −0.3  |
| Guanosine (G) | 200                                     | 195.0±12.0 | 12.7 | 4.1  | −2.5  |
|           | 600                                     | 630.4±21.8 | 6.4  | 2.7  | 5.1   |
|           | 8000                                    | 8472.0±280.3 | 4.3  | 3.1  | 5.9   |
|           | 80,000                                  | 78,180.0±1894.1| 4.5  | 1.9  | −2.3  |
| N6-Methyladenosine (m6A) | 40                                      | 36.2±2.0 | 13.8 | 1.9  | −9.5  |
|           | 120                                     | 131.2±6.9 | 2.4  | 5.6  | 9.3   |
|           | 1600                                    | 1733.3±96.0 | 7.2  | 5.2  | 8.3   |
|           | 16,000                                  | 15,806.1±196.9 | 1.2  | 1.2  | −1.2  |
| N5-Methylcytidine (m5C) | 40                                      | 38.4±1.6 | 2.1  | 4.3  | −4.0  |
|           | 120                                     | 122.3±3.3 | 4.2  | 2.3  | 1.9   |
|           | 1600                                    | 1697.3±39.9 | 6.0  | 0.6  | 6.1   |
|           | 16,000                                  | 15,726.7±286.5 | 3.3  | 1.4  | −1.7  |
The mean concentration levels of m6A and m5C in prepared test samples of mice liver mRNA in the control and Epimedin C-induced liver injury model groups are presented in Fig. 4. The ratios of m6A to A (m6A/A% = Cm6A/CA × %) and m5C to C (m5C/C% = Cm5C/CC × %) expressed the content of modified nucleoside in mouse liver mRNA. The results showed that both the concentration levels of m6A and m5C, and the ratio of m6A/A and m5C/C in the mRNA of in Epimedin C-induced mice live injury mice were significantly increased when compared with the normal control mice. According to these results, it could be indicated that epigenetic modification in mice liver were impacted by Epimedin C treatment.

### Table 3  The stability test results in enzymolysis matrix under various storage conditions (n = 5)

| Analytes Added (pg/mL) | Room temperature for 6 h | Autosampler for 20 h (RT) | Three freeze–thaw cycles | Freezing for 30 days (− 20°C) |
|------------------------|--------------------------|---------------------------|--------------------------|-------------------------------|
|                        | Measured (pg/mL) RE (%)  | Measured (pg/mL) RE (%)  | Measured (pg/mL) RE (%)  | Measured (pg/mL) RE (%)      |
| Adenosine 120          | 130.0 ± 2.1 8.3           | 130.0 ± 1.0 10.8          | 134.2 ± 3.6 11.8          | 133.0 ± 1.6 10.8             |
| 16,000                 | 15,360.0 ± 230.2 − 4.0   | 15,380.0 ± 164.3 − 3.9   | 15,240.0 ± 54.8 − 4.8    | 14,840.0 ± 167.3 − 7.3       |
| Uridine 6000           | 6316.0 ± 170.7 5.3       | 6052.0 ± 169.0 0.9       | 5986.0 ± 141.2 − 0.2     | 5868.0 ± 140.2 − 2.2         |
| 800,000                | 706,000.0 ± 12308.5 − 11.8 | 688,800.0 ± 6760.2 − 13.3 | 687,200.0 ± 15,073.2 − 14.1 | 716,600.0 ± 13,794.9 − 10.4 |
| Cytidine 120           | 120.8 ± 2.9 0.7          | 121.0 ± 1.9 0.8          | 119.0 ± 4.4 − 0.8         | 117.2 ± 4.1 − 2.3            |
| 16,000                 | 16,140.0 ± 240.8 0.9     | 16,040.0 ± 230.2 0.3     | 16,080.0 ± 238.7 0.5     | 15,980.0 ± 228.0 − 0.1        |
| Guanosine 600          | 653.0 ± 16.3 8.8         | 625.8 ± 14.8 4.3         | 628.2 ± 14.8 4.7         | 605.2 ± 28.1 0.9             |
| 80,000                 | 79,200.0 ± 748.3 − 1.0   | 77,520.0 ± 1158.4 − 3.1  | 76,300.0 ± 1647.7 − 4.6  | 77,320.0 ± 2008.0 − 3.4       |
| m6A 120                | 132.4 ± 3.0 10.3         | 126.0 ± 3.4 5.0          | 123.8 ± 3.0 3.2          | 132.2 ± 12.1 10.2             |
| 16,000                 | 15,962.0 ± 205.7 − 0.2   | 15,561.0 ± 218.9 − 2.7   | 15,490.8 ± 269.4 − 3.2   | 15,841.8 ± 281.8 − 1.0        |
| m5C 120                | 123.4 ± 3.8 2.8          | 121.6 ± 2.2 1.3          | 120.0 ± 2.2 0            | 122.2 ± 3.7 1.8               |
| 16,000                 | 15,720.0 ± 130.4 − 1.8   | 15,600.0 ± 100.0 − 2.5   | 15,600.0 ± 308.2 − 2.5   | 15,980.0 ± 249.0 − 0.1        |

### Table 4  Precision and accuracy of the dilution QC samples (n = 5)

| Analytes Added (ng/mL) | Dilution factor | Calculated (pg/mL) | Measured (pg/mL) | RSD (%) | RE (%) |
|------------------------|-----------------|--------------------|------------------|---------|--------|
| Adenosine 12           | 100             | 120                | 137.8 ± 2.2      | 1.6     | 14.8   |
| 1600                   | 100             | 16,000             | 14,940.0 ± 167.3 | 1.1     | − 6.6  |
| Uridine 600            | 100             | 600                | 58620.0 ± 99.3   | 1.7     | − 2.3  |
| 80,000                 | 100             | 800,000            | 716,000.0 ± 10,583.0 | 1.5     | − 10.5 |
| Cytidine 12            | 100             | 120                | 115.8 ± 5.4      | 4.6     | − 3.5  |
| 1600                   | 100             | 16,000             | 16,100.0 ± 339.1 | 2.1     | 0.6    |
| Guanosine 60           | 100             | 600                | 633.2 ± 26.0     | 4.1     | 5.9    |
| 8000                   | 100             | 8000               | 78,920.0 ± 1856.6 | 2.4     | − 1.4  |
| m6A 12                 | 100             | 120                | 126.4 ± 10.2     | 8.0     | 5.3    |
| 1600                   | 100             | 16,000             | 15,631.2 ± 212.5 | 1.4     | − 2.3  |
| m5C 12                 | 100             | 120                | 125.8 ± 4.5      | 3.6     | 4.8    |
| 1600                   | 100             | 16,000             | 16,540.0 ± 320.9 | 1.9     | 3.4    |

### Application for quantifying the nucleosides

The mean concentration levels of m6A and m5C in prepared test samples of mice liver mRNA in the control and Epimedin C-induced liver injury model groups are presented in Fig. 4. The ratios of m6A to A (m6A/A% = Cm6A/CA × %) and m5C to C (m5C/C% = Cm5C/CC × %) expressed the content of modified nucleoside in mouse liver mRNA. The results showed that both the concentration levels of m6A and m5C, and the ratio of m6A/A and m5C/C in the mRNA of in Epimedin C-induced mice live injury mice were significantly increased when compared with the normal control mice. According to these results, it could be indicated that epigenetic modification in mice liver were impacted by Epimedin C treatment.

### Discussion

Some studies indicated that the Epimedin C had the potential hepatotoxicity [6–8], but the mechanism of Epimedin C-induced liver injury has not been studied. In this study, the Epimedin C-induced liver injury mouse model was established for the first time. The oral dose (10 mg/kg, equivalent dose) of Epimedin C in mouse model is calculated according to the clinical dosage of Epimedin C in the Xian-Ling-Gu-Bao capsule. Meanwhile, four times equivalent dose (40 mg/kg) of Epimedin C was also investigated for the liver injury mouse model. The results showed that the mouse model was induced successfully by intragastrical administration Epimedin C at a daily dose of 40 mg/kg for 4 weeks in mice. The mouse model provides useful...
Fig. 3 Representative photomicrographs of liver histopathological examination and serum aminotransferase levels after Epimedin C treatment. A Epimedin C was absent in the normal control group; B the mice were treated with Epimedin C (10 mg/kg) in the EL group; C the mice were treated with Epimedin C (40 mg/kg) in the EH group. *P < 0.05 vs. the normal control group. The black arrow represents the vacuolar degeneration and the red arrow stands for the inflammatory cell infiltration.

Fig. 4 Concentration levels of six nucleosides and relative contents of m^6^A and m^5^C in test samples. The concentration levels of A A, B U, C C, D G, E m^6^A and F m^5^C in test samples; G, H the content of modified nucleoside m^6^A (ratio of m^6^A/A) and m^5^C (ratio of m^5^C/C). Epimedin C was absent in the normal control group. The mice were treated with Epimedin C (10 mg/kg) in the EL group. The mice were treated with Epimedin C (40 mg/kg) in the EH group. *P < 0.05 and **P < 0.01 vs. the normal control group.
tools for evaluating the hepatotoxicity and mechanism of Epimedin C in future studies.

To the best of our knowledge, methylation modification disorders of mRNA are closely related to the occurrence and development of many liver diseases. The study of investigating the connection of mRNA methylation and Epimedin C-induced liver injury was performed. A new UPLC-MS/MS method was developed for simultaneously determination of six nucleosides in mice liver mRNA. Compared to previous reports, this present method has higher sensitivity, wider linear range, and more analytes. Due to consisting of multiple compounds in mRNA, the simultaneous quantitation of six nucleoside encounters the great challenge in short running time using UPLC. Multiple reaction monitoring, a highly specific technique, was used for quantifying the targeted analyte without the considering of baseline chromatographic separation [25]. Furthermore, ultra-purified water containing 0.1% formic acid/methanol in a linear gradient was the optimum mobile phase to achieve the chromatogram. Because of the much higher concentrations of A, U, C and G than that of m6A and m5C, different ranges were designed for the standard curves. In addition, saturation nonlinearity is unavoidable in the highly sensitive mass spectrometric detector, when the concentrations of analytes are too high. In this study, the concentrations of A, U, C and G in the samples were above the upper limit of standard curves. Therefore, the samples were diluted 100-fold with blank enzyme matrix when detecting A, U, C and G.

Although one study has reported the content of m6A in liver mRNA of drug-induced liver injury mouse model [14], m5C alteration in liver injury mouse model is discovered firstly in our study. Additionally, it is the first time to reveal mRNA methylation alteration in liver mRNA of liver injury mice induced by Chinese herbal medicine. Our study validates the changes of m6A and m5C in mice liver mRNA after Epimedin C treatment, but the relationship between modified nucleosides and the mechanism of Epimedin C-induced liver injury is not well understood, which requires further investigation. This study may offer a new idea and approach for studying the mechanism of Epimedin C-induced liver injury.

Conclusions
An UPLC-MS/MS method for the simultaneous determination of A, U, C, G, m6A and m5C in mRNA was presented and validated. The method was applied to the detection of six nucleosides in liver mRNA of Epimedin C-induced liver injury mice. The results demonstrated that epigenetic modification changed in mice liver after Epimedin C treatment with test dose, and the m6A and m5C might be associated with Epimedin C-induced liver injury, which were reported for the first time. Our study provides a new idea for further research on the mechanism of Epimedin C or herbal medicine-induced liver injury.

Abbreviations
A: Adenosine; U: Uridine; C: Cytidine; G: Guanosine; m6A: N6-Methyladenosine; m5C: N5-Methylcytidine; ME: Matrix effect; MRM: Multiple reaction monitoring; mRNA: Messenger ribonucleic acid; ALT: Alanine transaminase; AST: Aspartate transaminase; UPLC-MS/MS: Ultra-high performance liquid chromatography tandem mass spectrometry; QC: Quality control.

Acknowledgements
Not applicable.

Authors’ contributions
XT and ZZS conceived and designed the study and drafted the initial manuscript; ZZS, ZYL and XQW performed the experiments and contributed to the initial data analysis. ZZS and XQW prepared figures and tables. ZYL, RJL and XT revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 31870809 and 81903720), and Province and Ministry Co-construction Major Project of the Medical Science and Technique Foundation of Henan Province (Grant No. SBGJ202001007).

Availability of data and materials
The datasets supporting the conclusion of this article are included within the article and its additional files.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
There are no competing interests.

Author details
1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China. 2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou, People’s Republic of China.

Received: 17 June 2021 Accepted: 4 September 2021
Published online: 21 September 2021

References
1. Shen T, Liu YX, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156(8):2230–2241.e2211.
2. Huang S, Meng N, Chang BQ, Quan XH, Yuan RY, Li B. Anti-inflammatory activity of Epimedium brevicornu Maxim ethanol extract. J Med Food. 2018;21(7):726–33.
3. Zhang YJ, Huang RQ, Wu L, Wang Y, Jin TE, Liang Q. The complete chloroplast genome of Epimedium brevicornu Maxim (Berberidaceae), a traditional Chinese medicine herb. Mitochondrial DNA B Resour. 2020;5(1):588–90.
4. Ai L, Yi WM, Chen LD, Wang HB, Huang QH. Xian-Ling-Gu-Bao protects osteoporosis through promoting osteoblast differentiation by targeting miR-100-SpiKDM6B/RUNX2 axis. In Vitro Cell Dev Biol Anim. 2021;57(1):3–9.
5. Wu H, Zhong QX, Wang J, Wang M, Fang F, Xia Z, et al. Beneficial effects and toxicity studies of Xian-ling-gu-bao on bone metabolism in ovariectomized rats. Front Pharmacol. 2017;8:273.

6. Xie JC, Xu H, Jiang JC, Zhang N, Yang J, Zhao J, et al. Characterization of a novel thermostable glucose-tolerant GH1 beta-glucosidase from the hyperthermophile Ignisphaera aggregans and its application in the efficient production of baohuoside I from icaritin and total epimedium flavonoids. Bioorg Chem. 2020;104:104296.

7. Cheng Y, Yang ZL, Shi J, Yang JJ, Zhao XG, He YH, et al. Total flavonoids of Epimedium ameloites testicular damage in streptozotocin-induced diabetic rats by suppressing inflammation and oxidative stress. Environ Toxicol. 2020;35(2):268–76.

8. Zhang L, Wang T, Zhao BS, Zhang JX, Yang S, Fan CL, et al. Effect of 2’-O-rhamnosyl icariside II, baohuoside I and baohuoside II in Herba Epimedi on cytotoxicity indices in HL-7702 and HepG2 cells. Molecules. 2019;24(7):1263.

9. Nombela P, Miguel-Lopez B, Blanco S. The role of m(6)A, m(5)C and Psi RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20(1):18.

10. Xie SS, Chen WW, Chen KH, Chang YY, Yang F, Lin AF, et al. Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int. 2020;20(1):385.

11. Chellamuthu A, Gray SG. The RNA methyltransferase NSUN2 and its potential roles in cancer. Cells. 2020;9(3):978.

12. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, et al. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6)-methyladenosine-dependent primary microRNA processing. Hepatology. 2017;65:529–43.

13. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-methyladenosinyl transferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67:2254–70.

14. Liu RJ, Zhao F, Wei JY, Yu P, Zhang J, Wang YQ, et al. Determination of five nucleosides by LC-MS/MS and the application of the method to quantify N2-methyladenosine level in liver messenger ribonucleic acid of an acetaminophen-induced hepatotoxicity mouse model. J Sep Sci. 2019;42(16):2668–78.

15. Jian H, Zhang C, Qi ZY, Li XY, Lou YF, Kang Y, et al. Alteration of mRNA 5'-methylcytosine modification in neurons after OGD/R and potential roles in cell stress response and apoptosis. Front Genet. 2021;12:633681.

16. Zhang QY, Zheng QY, Yu X, He YT, Guo WZ. Overview of distinct 5-methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues. J Transl Med. 2020;18(1):245.

17. Chang JS, Lin ZX, Liu YJ, Yang SM, Zhang Y, Yu XY. Ultra performance liquid chromatography–tandem mass spectrometry assay for the quantification of RNA and DNA methylation. J Pharm Biomed Anal. 2021;197:113969.

18. Guo MZ, Liu DT, Sha Q, Geng HF, Liang J, Tang DQ. Succinic acid enhanced quantitative determination of blood modified nucleosides in the development of diabetic nephropathy based on hydrophilic interaction liquid chromatography mass spectrometry. J Pharm Biomed Anal. 2019;164:309–16.

19. Cui YX, Liang Z, Shen LS, Zhang Q, Bao SJ, Geng YK, et al. S-Methylcytosine RNA methylation in Arabidopsis thaliana. Mol Plant. 2017;10(11):1387–99.

20. Fu L, Amato NJ, Wang P, McGowan SJ, Niedernhofer LJ, Wang Y. Simultaneous quantification of methylated cytidine and adenosine in cellular and tissue RNA by nano-flow liquid chromatography–tandem mass spectrometry coupled with the stable isotope-dilution method. Anal Chem. 2015;87(15):7653–9.

21. Zhu YT, Zhou GY, Yu XB, Xu Q, Wang K, Xie D, et al. LC-MS–MS quantitative analysis reveals the association between FTO and DNA methylation. PLoS ONE. 2017;12(4):e0175849.

22. Hsu PJ, Shi H, Zhu AC, Lu Z, Miller N, Edens BM, et al. The RNA-binding protein FMRP facilitates the nuclear export of N6-methyladenosine-containing miRNAs. J Biol Chem. 2019;294(52):19889–95.

23. U.S. Department of Health and Human Services (DHHS), Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), Guidance for Industry, bioanalytical method validation. 2013.

24. Chinese Pharmacopoeia Commission, Chinese Pharmacopoeia, Guiding principle for bioanalytical method validation. 2015.

25. Hu Y, Wang Z, Xia FB, Yang W, Liu YC, Wan JB. Simultaneous quantification of bioactive components in Chinese herbal spirits by ultra-high performance liquid chromatography coupled to triple-quadrupole mass spectrometry (UHPLC–QQQ–MS/MS). Chin Med. 2021;16(1):26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.